Showing 2951-2960 of 5956 results for "".
- Clearside Biomedical Announces Multiple Presentations Delivered at the ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-announces-multiple-presentations-delivered-at-the-asrs-annual-meeting/2479557/Clearside Biomedical announced that multiple oral presentations were delivered on Clearside’s pipeline and proprietary SCS Microinjector targeting the suprachoroidal space (SCS) at the American Society of Retinal Specialists (ASRS) Annual Meeting. “Clearside had a widespread presence at t
- EssilorLuxottica, Maker of Ray-Ban Sunglasses, Agrees to Buy GrandVision in $8 Billion Dealhttps://modernod.com/news/ray-ban-maker-agrees-to-buy-grandvision-for-8-billion/2479558/A blockbuster deal in the eyecare retail space was announced on Wednesday as EssilorLuxottica, the maker of Ray-Ban sunglasses, agreed to buy Dutch retailer GrandVision NV in multi-billion dollar deal. Paris-based EssilorLuxottica agreed to buy control (77%) of European rival GrandVision f
- Altris AI Algorithm for Detection of Retinal Conditions on OCT Scans Receives European CE Mark Approvalhttps://modernod.com/news/altris-ai-algorithm-for-detection-of-retinal-conditions-on-oct-scans-receives-european-ce-mark-approval/2479561/Altris AI announced that it has received the CE Mark approval for its Standard Functionality for retinal conditions detection on Optical Coherence Tomography (OCT) scans. Altris AI Standard Functionality is ready for preliminary screening of retinal diseases in clinical practice. Altris AI detect
- Ocular Therapeutix Announces Early Assignment of Permanent and Specific J-Code for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-early-assignment-of-permanent-and-specific-j-code-for-dextenza/2476773/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dextenza (dexamethasone ophthalmic insert) 0.4 mg, which is approved for the
- Glaukos Announces Global Licensing Agreement With Intratus, Maker of Noninvasive Drug Delivery Platformhttps://modernod.com/news/glaukos-announces-global-licensing-agreement-with-intratus/2476756/Glaukos announced that it has entered into a licensing agreement with privately held, early-stage life sciences company Intratus. Under terms of the deal, Intratus has granted Glaukos a global exclusive license to
- Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch ‘My Home In Sight’https://modernod.com/news/novartis-teams-up-with-celebrity-interior-designer-nate-berkus-to-launch-my-home-in-sight/2476753/Novartis is teaming up with celebrity interior designer Nate Berkus to launch “My Home in Sight,” a program that aims to raise awareness of the daily impact of wet age-related macular degeneration (AMD) and empower those living with wet AMD and their car
- New Age-Related Macular Degeneration Common in Untreated Fellow Eyeshttps://modernod.com/news/new-age-related-macular-degeneration-common-in-untreated-fellow-eyes/2476748/New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the VIEW 1 and VIEW 2 studies, as reported b
- Medicel Launches First 2-in-1 Lens Injection Systemhttps://modernod.com/news/medicel-launches-first-2-in-1-lens-injection-system/2476740/Medicel says it has launched the world’s first 100% 2-in-1 lens injector, the Accuject Dual. The new injector enables surgeons to operate either in push or screw mode, allowing more control. Unlike competitor dual-mode injectors on the market that are 50% push and 50% screw, the Accuject
- Foundation Fighting Blindness Appoints Judy Taylor Vice President, Developmenthttps://modernod.com/news/foundation-fighting-blindness-appoints-judy-taylor-vice-president-development/2476733/The Foundation Fighting Blindness has announced that it has appointed Judy Taylor as vice president, development. In her new role, Ms. Taylor will be responsible and accountable for the strategic direction, planning and oversight of major gifts and planned giving function for the foundation.
- Ocular Therapeutix Announces Christopher White as Senior Vice President, Head of Business and Corporate Developmenthttps://modernod.com/news/ocular-therapeutix-announces-christopher-white-as-senior-vice-president-head-of-business-and-corporate-development/2476725/Ocular Therapeutix announced the appointment of Christopher White as Senior Vice President, Head of Business and Corporate Development. “We are thrilled to welcome Chris to the Ocular team to oversee business and corporate development,” Antony Mattessich, President and Chief Executive Offi